AR025669A1 - METHODS AND COMPOSITIONS FOR THE MODULATION OF THE CAPACITY OF RESPONSE TO CORTICOSTEROIDS. - Google Patents
METHODS AND COMPOSITIONS FOR THE MODULATION OF THE CAPACITY OF RESPONSE TO CORTICOSTEROIDS.Info
- Publication number
- AR025669A1 AR025669A1 ARP000104830A AR025669A1 AR 025669 A1 AR025669 A1 AR 025669A1 AR P000104830 A ARP000104830 A AR P000104830A AR 025669 A1 AR025669 A1 AR 025669A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- patient
- corticosteroid
- preferred
- target
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee un método para modular la capacidad de respuesta a los corticosteroides en un paciente. En el método, un activo que antagoniza con un blanco odiana que regula la produccion de IFN-gama en el paciente se administra al individuo en combinacion con un corticosteroide, de manera tal que la capacidad derespuesta del paciente al corticosteroide se module, en comparacion a la administracion del corticosteroide solo al paciente. En una forma de realizacion, elagente es un antagonista de la IL-18. En otra forma de realizacion, el agente es un antagonista de la Interleucina-12 (IL-12). En otra forma de realizacionmás todavía, el agente es un antagonista de las células NK, En una forma de realizacion preferida, el agente es un inhibidor de una proteasa de la familia delas caspasas, con preferencia un inhibidor de la ICE. En otra forma de realizacion preferida, el agente es un anticuerpo monoclonal anti-IL-12. En otra formade realizacion preferida, el agente es un anticuerpo anti-asialo-GM1 o un anticuerpo NK1.1. Otros agentes preferidos incluyen los inhibidores de lafosfodiesterasa IV y los agonistas beta-2. Los métodos pueden emplearse en el tratamiento de una variedad de enfermedades y trastornos inflamatorios einmunologicos. También se proveen las composiciones farmacéuticas que comprenden un agente que antagoniza un blanco o diana que regula la produccion de IFN-gama en el paciente, un corticosteroide y un portador farmacéuticamente aceptable. Una composicion preferida comprende un inhibidor de la ICE, uncorticosteroide y un portador farmacéuticamente aceptable.A method is provided to modulate the ability to respond to corticosteroids in a patient. In the method, an asset that antagonizes an odian target that regulates the production of IFN-gamma in the patient is administered to the individual in combination with a corticosteroid, such that the patient's response capacity to the corticosteroid is modulated, compared to corticosteroid administration only to the patient. In one embodiment, the agent is an antagonist of IL-18. In another embodiment, the agent is an antagonist of Interleukin-12 (IL-12). In yet another embodiment, the agent is an NK cell antagonist. In a preferred embodiment, the agent is an inhibitor of a protease of the caspases family, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. In another preferred embodiment, the agent is an anti-Asialo-GM1 antibody or an NK1.1 antibody. Other preferred agents include laphosphodiesterase IV inhibitors and beta-2 agonists. The methods can be employed in the treatment of a variety of inflammatory diseases and eimmune disorders. Also provided are pharmaceutical compositions comprising an agent that antagonizes a target or target that regulates the production of IFN-gamma in the patient, a corticosteroid and a pharmaceutically acceptable carrier. A preferred composition comprises an ICE inhibitor, uncorticosteroid and a pharmaceutically acceptable carrier.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39855599A | 1999-09-17 | 1999-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR025669A1 true AR025669A1 (en) | 2002-12-11 |
Family
ID=23575827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000104830 AR025669A1 (en) | 1999-09-17 | 2000-09-14 | METHODS AND COMPOSITIONS FOR THE MODULATION OF THE CAPACITY OF RESPONSE TO CORTICOSTEROIDS. |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR025669A1 (en) |
AU (1) | AU7127600A (en) |
WO (1) | WO2001019373A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
WO2001097815A2 (en) * | 2000-06-22 | 2001-12-27 | Willy Ben Moussa Ben Mohammed | Use of glucocorticosteroids for producing a medicament to treat oligotrichia |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
EP1369118A1 (en) * | 2002-06-04 | 2003-12-10 | B.R.A.H.M.S Aktiengesellschaft | Process and agent for the prevention, inhibition and therapy of sepsis |
WO2004093907A2 (en) * | 2003-04-23 | 2004-11-04 | Tomoaki Hoshino | Therapeutic agents for treating dermatitis, alopecia and itching and transgenic animals for evaluating such therapeutic agents |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
CA2584169A1 (en) * | 2004-10-13 | 2006-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Remedies/preventives for chronic skin disease |
EA016022B1 (en) | 2004-12-21 | 2012-01-30 | Сентокор, Инк. | Isolated mammalian anti-il-12 antibody and method for altering the activity thereof |
AU2006270165B2 (en) | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
WO2007103373A2 (en) * | 2006-03-07 | 2007-09-13 | Combinatorx, Incorporated | Compositions and methods for the treatment of immunoinflammatory disorders |
PL2077830T3 (en) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Methods, compositions, and formulations for the treatment of thyroid eye disease |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
SG190878A1 (en) | 2010-11-24 | 2013-07-31 | Lithera Inc | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
WO2015063669A1 (en) | 2013-10-30 | 2015-05-07 | Wockhardt Limited | Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof |
CA3019164A1 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
TW201922780A (en) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | Safe and effective method of treating Lupus with anti-IL12/IL23 antibody |
WO2019220412A2 (en) | 2018-05-18 | 2019-11-21 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
PL3883606T3 (en) | 2018-09-24 | 2023-11-27 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody |
AU2020279987A1 (en) | 2019-05-23 | 2021-11-18 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2588474B1 (en) * | 1985-10-16 | 1987-11-27 | Cird | SYNERGETIC ANTI-INFLAMMATORY COMPOSITIONS BASED ON A CORTICOSTEROID AND AN AGONIST BETA |
JP3042866B2 (en) * | 1989-09-08 | 2000-05-22 | グラクソ・グループ・リミテッド | Respiratory disease drug |
BR9810409A (en) * | 1997-03-18 | 2000-08-22 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
CN1297354A (en) * | 1998-03-16 | 2001-05-30 | 西托维亚公司 | Dipeptide caspase inhibitors and use thereof |
-
2000
- 2000-09-08 WO PCT/US2000/024725 patent/WO2001019373A2/en active Search and Examination
- 2000-09-08 AU AU71276/00A patent/AU7127600A/en not_active Abandoned
- 2000-09-14 AR ARP000104830 patent/AR025669A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU7127600A (en) | 2001-04-17 |
WO2001019373A3 (en) | 2001-10-04 |
WO2001019373A2 (en) | 2001-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR025669A1 (en) | METHODS AND COMPOSITIONS FOR THE MODULATION OF THE CAPACITY OF RESPONSE TO CORTICOSTEROIDS. | |
WO1998041232A3 (en) | Compositions for modulating responsiveness to corticosteroids | |
Hu et al. | Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis | |
US6713463B2 (en) | Methods and compositions for treating and preventing mucositis | |
Walsh | Mast cells and oral inflammation | |
Bedossa et al. | Liver extracellular matrix in health and disease | |
Yoshimura et al. | The effects of bradykinin on ovulation and prostaglandin production by the perfused rabbit ovary | |
Genot et al. | Low-level laser for prevention and therapy of oral mucositis induced by chemotherapy or radiotherapy | |
Kaye et al. | Pharmacology of cyclooxygenase-2 inhibitors and preemptive analgesia in acute pain management | |
Yoon et al. | Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy | |
CN1151784C (en) | Quick absorption liquid composite | |
Galindo et al. | Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art | |
MXPA05004778A (en) | Methods of using and compositions comprising immunomudulatory compounds for the treatment and management of myeloproliferative diseases. | |
Nafarelin European Endometriosis Trial Group | Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up | |
BR0116558A (en) | Pharmaceutical composition in tablet, amylodipine free base, method of treatment or prevention of hypertension, angina or cardiac congestion, process, process for purification of amlodipine free base and particulate amlodipine free base population | |
GEP20043313B (en) | Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility | |
Bhatt et al. | Host modulatory agents in periodontics: A step towards the future | |
Krishna et al. | Role of serratiopeptidase and dexamethasone in the control of postoperative swelling | |
ATE210978T1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING USCHARINE | |
Panico et al. | Protective effects of benzisothiazolylamidines on IL-1β induced alterations in human articular chondrocyte metabolism | |
US11925656B2 (en) | Biological total joint replacement | |
Jiang et al. | Paeonol inhibits IL-1β induced expression of iNOS, COX-2, and MMPs through NF-κB activation: an in vitro and in vivo study | |
Virag et al. | Are the new staging rules better for T4 oral cancer? | |
Paulson | Treatment of superficial carcinoma of the bladder | |
Mohede et al. | Medical treatments of Peyronie's disease |